Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | MicrobiomeTrials
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2019-10-22Est. Completion: 2027-12-31
Enrollment target: 80 participants
Locations
M D Anderson Cancer Center, Houston, Texas, United States